<DOC>
	<DOC>NCT00049777</DOC>
	<brief_summary>The purpose of this study is to evaluate the relative efficacy and safety of prophylactic heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of severe sepsis in the adult.</brief_summary>
	<brief_title>A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Drotrecogin alfa activated</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion Criteria Adults greater than or equal to 18 years of age Receiving inpatient treatment for severe sepsis Indicated for treatment with Drotrecogin Alfa (Activated) under approved label in the country where the patient is enrolled Exclusion Criteria Contraindicated for heparin treatment Require a higher dose of heparin than defined in the trial Have acute or chronic renal failure with an estimated creatinine clearance less than 30mL/min Weigh more than 135 kg (297 pounds) Are not expected to survive 28 days given their medical condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>